Use of C-reactive protein to guide antibiotic therapy in hospitalized patients: a systematic review and meta-analysis
Authors:
Preprint
- 1 September 2022
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: C-reactive protein (CRP) is an acute-phase marker used in clinical practice to identify and monitor inflammatory and infectious processes. Recent data suggest that CRP might be useful in guiding antibiotic therapy discontinuation among critical care patients. This meta-analysis analyzed the benefits and risks of CRP-guided protocols to define antibiotic therapy discontinuation in hospitalized patients in comparison with standard treatment. Methods: Studies were searched in four databases: Medline, Embase, CENTRAL, and LILACS. The reference lists of the articles retrieved, and related review studies were hand-screened to find eligible trials that might have been missed. Primary endpoints included the duration of antibiotic therapy for the index episode of infection. The secondary endpoint was the all-cause hospital mortality and infection relapses. Risk of bias was evaluated using the Cochrane Risk of Bias 2.0 tool. Random effects were used to pool the mean differences and odds ratio of individual studies. The protocol was registered in PROSPERO (CRD42021259977).Results: The search strategy retrieved 5209 titles, out of which 03 studies met the eligibility criteria and were included in this meta-analysis. 727 patients were analyzed, of whom 278 were included in the intervention group and 449 were included in the control group. 55,7% of all patients were women. Meta-analysis indicated that experimental groups (CRP-guided) had a shorter duration of antibiotic therapy (days) [MMD= -1.82, 95%IC -3.23; -0.40], with no difference in mortality [OR =1.19 95%IC 0.67-2.12] or occurrence of infection relapse [OR =3.21 95%IC 0.85-12.05] between the two groups. Conclusion: The use of CRP-guided protocol reduced the total amount of time required for antibiotic therapy when compared to standard protocols of treatment in hospitalized patients with an acute bacterial infection. We did not observe statistical differences in mortality and infection relapse rates.Keywords
All Related Versions
- Version 1, 2022-09-01, Research Square
- Published version: BMC Infectious Diseases, 23 (1), 1.
This publication has 11 references indexed in Scilit:
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysisThe Lancet Infectious Diseases, 2018
- The current status of biomarkers for the diagnosis of nosocomial pneumoniasCurrent Opinion in Critical Care, 2017
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016Intensive Care Medicine, 2017
- Rayyan—a web and mobile app for systematic reviewsSystematic Reviews, 2016
- Procalcitonin Versus C-Reactive Protein for Guiding Antibiotic Therapy in SepsisCritical Care Medicine, 2013
- Serum Procalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection: A Systematic Review and Meta-analysisClinical Infectious Diseases, 2004
- C-reactive protein: a valuable marker of sepsisIntensive Care Medicine, 2002
- Potential clinical applications of c‐reactive proteinJournal of Clinical Laboratory Analysis, 1990
- Specificity of C-Reactive Protein for Choline Phosphate Residues of Pneumococcal C-PolysaccharideExperimental Biology and Medicine, 1971